COVID-19 and Lipid Disorders
Authors:
- 14 July 2022
- journal article
- review article
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 54 (08) , 514-521
Abstract
An elevated cholesterol concentration has been suspected to increase the susceptibility for SARS-COV-2 infection. Cholesterol plays a central role in the mechanisms of the SARS-COV-2 infection. In contrast, higher HDL-cholesterol levels seem to be protective. During COVID-19 disease, LDL-cholesterol and HDL-cholesterol appear to be decreased. On the other hand, triglycerides (also in different lipoprotein fractions) were elevated. Lipoprotein(a) may increase during this disease and is most probably responsible for thromboembolic events. This lipoprotein can induce a progression of atherosclerotic lesion formation. The same is suspected for the SARS-COV-2 infection itself. COVID-19 patients are at increased risk of incident cardiovascular diseases, including cerebrovascular disorders, dysrhythmias, ischemic and non-ischemic heart disease, pericarditis, myocarditis, heart failure, and thromboembolic disorders. An ongoing lipid-lowering therapy, including lipoprotein apheresis, is recommended to be continued during the COVID-19 disease, though the impact of lipid-lowering drugs or the extracorporeal therapy on prognosis should be studied in further investigations.Keywords
This publication has 45 references indexed in Scilit:
- Declined serum high density lipoprotein cholesterol is associated with the severity of COVID-19 infectionClinica Chimica Acta, 2020
- Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular ScienceCardiovascular Research, 2020
- Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable HypothesisCurrent Atherosclerosis Reports, 2020
- Cardiovascular diseases, lipid-lowering therapies and European registries in the COVID-19 pandemicCardiovascular Research, 2020
- Is There a Role for Environmental and Metabolic Factors Predisposing to Severe COVID-19?Hormone and Metabolic Research, 2020
- Soluble LOX‐1: A Novel Biomarker in Patients With Coronary Artery Disease, Stroke, and Acute Aortic Dissection?Journal of the American Heart Association, 2020
- Effect of statins on atherosclerotic plaqueTrends in Cardiovascular Medicine, 2019
- Contribution of lectin-like oxidized low-density lipoprotein receptor-1 and LOX-1 modulating compounds to vascular diseasesVascular Pharmacology, 2018
- NAD(P)H Oxidase and Endothelial DysfunctionHormone and Metabolic Research, 2008
- Low-density Lipoproteins Induce the Renin-Angiotensin System and their Receptors in Human Endothelial CellsHormone and Metabolic Research, 2007